Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Julphar
AstraZeneca
US Army
QuintilesIMS
Deloitte

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,351,401

« Back to Dashboard

Which drugs does patent 7,351,401 protect, and when does it expire?

Patent 7,351,401 protects VIZAMYL and is included in one NDA.

This patent has fifty-seven patent family members in nineteen countries.

Summary for Patent: 7,351,401
Title:Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
Inventor(s): Klunk; William E. (Pittsburgh, PA), Mathis, Jr.; Chester A. (Pittsburgh, PA), Wang; Yanming (Imperial, PA)
Assignee: University of Pittsburgh (Pittsburgh, PA)
Application Number:10/859,600
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,351,401
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 7,351,401

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y DIAGNOSTIC RADIOIMAGING ➤ Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y DIAGNOSTIC RADIOIMAGING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,351,401

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001286702 ➤ Sign Up
Australia 2004221897 ➤ Sign Up
Australia 2008202626 ➤ Sign Up
Australia 2011200667 ➤ Sign Up
Australia 8670201 ➤ Sign Up
Brazil 0113470 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Federal Trade Commission
Argus Health
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.